📰 Rd Division News
Page 3 - Rd Division News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Rd Division. Real-time updates on events, politics, business and more.
May 26, 2023
Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the... | May 26, 2023
May 11, 2023
2023 News Releases May 11, 2023 GHG Provides Update on Apollon Transaction Apr 28, 2023 GHG Concludes First U.S.... | May 11, 2023
April 28, 2023
Vancouver, British Columbia--(Newsfile Corp. - April 28, 2023) - GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) ("GHG" or the "Company") is pleased to announce that the Company has executed
April 28, 2023
Roorkee: Indian Institute of Technology Roorkee (IIT Roorkee) Department of Design organized a two day Industry Academia Meet from April 22-23, 2023. The objective of Academia Meet - Insight on Innovation: Success Stories - was to provide a pla
April 25, 2023
· Executive Vice President Yong Wha Kim is a R&D specialist with experience in key areas, including: - Automotive hardware and... | April 25, 2023
April 20, 2023
2023 News Releases Apr 20, 2023 GHG Announces Brokered Private Placement Apr 4, 2023 GHG Final Payment on Exclusive... | April 20, 2023
April 4, 2023
Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) ("GHG" or the "Company") is pleased to announce that it has completed its
April 1, 2023
2023 News Releases Mar 31, 2023 1st tranche PP Mar 30, 2023 Jeff Nagel joins as Product Manufacturing Advisor ... | April 1, 2023
March 30, 2023
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2023) - GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) ("GHG" or the "Company") is pleased to announce that Jeff Nagel has joined
March 27, 2023
Japan’s Ministry of Health, Labor and Welfare has approved fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2-low unresectable or recurrent breast cancer after prior chemotherapy.